InflaRx N.V. (NASDAQ: IFRX) announced it has regained compliance with Nasdaq's minimum bid price requirement, according to a notice received from the exchange's Listing Qualifications Department dated April 27, 2026.

The biopharmaceutical company met the requirement after its ordinary shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days from April 13 through April 24, 2026. Nasdaq has closed the matter.

The minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) mandates that listed companies maintain a minimum bid price to continue trading on the exchange.

InflaRx develops anti-inflammatory therapeutics targeting the complement system. The company's lead program is izicopan, an oral small molecule inhibitor being developed for inflammatory diseases including hidradenitis suppurativa. The company also developed vilobelimab, an intravenous anti-C5a monoclonal antibody.

Founded in 2007, InflaRx operates offices in Jena and Munich, Germany, and Ann Arbor, Michigan. The company's wholly owned subsidiaries include InflaRx GmbH in Germany and InflaRx Pharmaceuticals Inc. in the United States.